Target
Programmed death-1 (PD-1)
37 abstracts
Abstract
Two phase 2A clinical trials to evaluate the safety and efficacy of IMSA101 in combination with radiotherapy and checkpoint inhibitors in oligometastatic and oligoprogressive solid tumor malignancies.Org: MetroHealth Cancer Center, University of Wisconsin Madison, Cleveland VA,
Abstract
Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update.Org: Frauenshuh Cancer Center, Nimbus Therapeutics, Florida Cancer Affiliates, Honor Health Research Institute,
Abstract
Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.Org: Bristol Myers Squibb, Oncosite Centro de Pesquisa Clínica em Oncologia, Puerta de Hierro University Hospital, Madrid, Spain, Dana-Farber Cancer Institute, Boston, MA, USA, McGill University Health Centre, Montreal, QC, Canada,
Abstract
A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design.Org: Davis Comprehensive Cancer Center, Swog Gu Bladder Patient Advocate,
Abstract
Overestimation of survival in individuals with cancer treated in the real world with new cancer drugs: A population-based cohort study.Org: BC Cancer-Vancouver Centre, University of British Columbia,
Abstract
A prospective phase 2 single-arm study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (Keypoint-1).Org: Division of Thoracic Surgery,
Abstract
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.Org: Boehringer Ingelheim (Canada) Ltd,
Abstract
PD-1 checkpoint inhibitors related immune-mediated hepatitis in colon cancer: A systematic review and meta-analysis.Org: New York Medical College - Saint Michael's Medical Center, Landmark Medical Center,
Abstract
Safety and efficacy of camrelizumab and apatinib in combination with IMRT in unresectable hepatocellular carcinoma: A non-randomised phase 2 study.Org: Department of Hepatopancreatobiliary Surgery Unit I,
Abstract
A single institution review of immunotherapy use, adverse events, and outcomes in early-onset cancer.Org: University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, University Hospitals Center for Clinical Research, Case Western Reserve University School of Medicine, University Hospitals Sussex NHS Foundation Trust,
Abstract
Linking the companion diagnostic function of cancer genome profiling to therapy: Investigation of TMB-high predictors.Org: Hiroshima Prefectural Hospital, Hiroshima City North Medical Center Asa Citizens Hospital, JA Onomichi General Hospital, JA Hiroshima General Hospital,
Abstract
A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer.Org: Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Sun Yat-Sen University Cancer Center, Guangzhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Real-world treatment patterns and outcomes of patients with advanced melanoma treated with nivolumab plus relatimab.Org: Georgetown University School of Medicine,
Abstract
Use of immunotherapy with check point inhibitors in soft tissue sarcoma: Analysis from single institution.Org: University of Louisville, James Graham Brown Cancer Center,
Abstract
First-line (1L) systemic therapy in locally advanced/metastatic urothelial cancer (Ia/mUC): A living interactive systematic review and network meta-analysis.Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Division of Hematology and Medical Oncology, Mayo Clinic, Phoeniz, AZ,
Abstract
Efficacy and safety of PD-1 inhibitors plus metronomic oral vinorelbine in elderly pre-treated patients with metastatic non-small-cell lung cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate.Org: Princess Alexandra Hospital and Faculty of Medicine at University of Queensland, Royal Brisbane & Womens Hospital,
Abstract
Brain metastases in patients with pleural mesothelioma receiving dual checkpoint blockade compared to single-agent checkpoint blockade or chemotherapy.Org: Hospital of the University of Pennsylvania, Perelman School of Medicine, Penn Medicine at Lancaster General Health, University of Pennsylvania, Abramson Cancer Center,
Abstract
Patterns of pembrolizumab use for recurrent cervical cancer.Org: Columbia University Medical Center, Merck & Co., Inc., Herbert Irving Comprehensive Cancer Center,
Abstract
Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.Org: Copenhagen University Hospital, Washington University School of Medicine, ModernaTX, Rigshospitalet, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit,
Abstract
Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc).Org: Helios Klinikum Berlin-Buch, Charité–Universitätsmedizin Berlin, Medizinische Fakultät “Carl Gustav Carus“ der TU Dresden, Universitätsklinikum Würzburg, Universität Heidelberg,
Abstract
First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.Org: Horizon Oncology & Research Center, Merck & Co., Inc., Lyvgen Biopharma Holdings, Department of Investigational Cancer Therapeutics,
Abstract
Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer.Org: Memorial Sloan Kettering Cancer Center, Sorbonne University and Saint-Antoine Hospital, Pitié Salpêtrière Hospital, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.Org: Dana-Farber Cancer Institute, University of Pennsylvania, The Cancer Institute Hospital of JFCR, Tokyo, Japan, University of California Comprehensive Cancer Center, University of North Carolina at Chapel Hill,
Abstract
Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).Org: James P. Wilmot Cancer Center/URMC - JPWCC, Memorial Sloan Kettering Cancer Center,
Abstract
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.Org: Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Maternal and Child Health Hospital of Jiangxi Province, Shandong Cancer Hospital & Institute, The Affiliated Tumor Hospital of Zhengzhou University, The First Affiliated Hospital of Soochow University,
Abstract
Stereotactic ablative radiotherapy with nivolumab for early-stage operable non-small cell lung cancer: A phase 2 study.Org: Hospital Israelita Albert Einstein,
Abstract
Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, UT Southwestern Medical Center, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Department of Medicine, Section of Hematology/Oncology, Knapp Center for Biomedical Discovery, The University of Chicago, MSMC,
Abstract
Integrated survival analysis.Org: Cedars-Sinai Comprehensive Cancer Center, The Angeles Clinic and Research Institute, Marymount University Hospice,
Abstract
Fruquintinib versus fruquintinib combined with PD-1 inhibitors for metastatic colorectal cancer: Real-world data.Org: State Key Laboratory of Oncogenesis and Related Genes, Department of Oncology, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Oncology, Renji Hospital, Shanghai Jiaotong University Medicine School,
Abstract
Venous infusion chemotherapy (VIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.Org: Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Department of Radiology, Sun Yat-sen Memorial hospital of Sun Yat-sen university, Guangzhou, China,
Abstract
Pathologic complete response (pCR) to neoadjuvant treatment (NAT) with carboplatin, nab-paclitaxel and anthracycline in early and locally advanced triple-negative breast cancer (TNBC).Org: Medical Oncology Department, University Hospital Virgen del Rocío, Sevilla, Spain, Medical Oncology Department, University Hospital Puerto Real, Cádiz, Spain, Medical Oncology Department, University Hospital Virgen Macarena, Sevilla, Spain, University Hospital Virgen del Rocío, Sevilla, Spain, Hospital Virgen del Rocio de Sevilla. GEICAM Spanish Breast Cancer Group, Seville, Spain,
Abstract
Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting.Org: Mayo Clinic, University of Missouri–Kansas City, Mayo Clinic Florida,
Abstract
Trends in FDA approval of solid tumor therapies with analysis of single-agent vs. combination therapies.Org: Oregon Health and Sciences University, University of California Riverside, Medical Oncology Group, Oregon Health & Science University, Oregon Health & Science University, Department of Medicine, Division of Hematology and Medical Oncology, Knight Cancer Institute,
Abstract
Nivolumab as second-line treatment of patients with metastatic renal cell carcinoma with high or normal fibrinogen levels: A prospective, cohort study.Org: Bureau for Cancer Research - BUCARE, City Clinical Cancer Hospital No. 1, Institute of Oncology Angel H Roffo, Hadassah Medical Moscow, State Budgetary Healthcare Institution Saint-Petersburg Clinical Scientific and Practical Center for Specialised Types of Medical Care,
Abstract
Utility of circulating tumor DNA as a tool to detect minimal residual disease in patients with metastatic cancer and durable response following treatment with immune checkpoint inhibitors.Org: Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Hanover Medical School, NHS Greater Glasgow and Clyde, Dartmouth College/Giesel School of Medicine, Dartmouth-Hitchcock Medical Center,
Abstract
Circulating tumor DNA (ctDNA) dynamics in response to checkpoint inhibitor immunotherapy in colorectal cancer.Org: University Hospitals Cleveland Medical Center, Cleveland, OH, Case Western Reserve University School of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center,